

Date: 16th February, 2022

To, Listing Department, BSE Limited, Floor 25, PJ Tower Dalal Street, Mumbai – 400 001 Script Code: 540359

Dear Sirs,

<u>Subject: Submission of Advertisement Clipping of Extract of the Unaudited Financial Results for the quarter and nine months ended 31st December, 2021</u>

In terms of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached a copy of the advertisement clipping of Extract of the Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2021 published in Financial Express (English and Gujarati) Edition dated 16th February, 2022 which were approved at the Board Meeting of the Company held on Monday, 14th February, 2022.

Thanking you,

Yours faithfully,

For, Parmax Pharma Limited

Yash J. Vora Company Secretary

Encl: As above

यूनियम बैंक (S) Union Bank

Veraval Branch: Bhidiya Near Rameshwar Petrol Pump Somnath Road Veraval Veraval - 362265

[Rule 8(1)] POSSESSION NOTICE (For immovable property)

Whereas, The undersigned being the authorised officer of Union Bank of India, Bhidiya, Near Rameshwar Petrol Pump, Somnath Road, Veraval - 362265 under the Securitisation and Reconstruction of Financial Assets and Enforcemen Security Interest Act, 2002 (Act No. 54 of 2002) and in exercise of powers conferred under Section 13(12) read with rule 3 of the Security Interest (Enforcement) Rules 2002 issued a demand notice dated 11.10.2021 calling upon the borrower M/S Narmada Sea Food, Prop. Mr. Jayesh Babubhai Khapandi & Guarantor : Mr. Agiya Dipakbhai Jayantilal to repay the amount mentioned in the notice being Rs. 13,41,790.55 (Rupees Thirteen Lakhs Forty One Thousand Seven Hundred Ninety and Fifty Five Paisa only) within 60 days from the date of receipt of the said

The borrower having failed to repay the amount, notice is hereby given to the borrower and the public in general that the undersigned has taken possession of the property described herein below in exercise of powers conferred on him/her under Section 13(4) of the said Act read with rule 8 of the said rules on this 10th Day of February 2022.

The borrower in particular and the public in general is hereby cautioned not to deal with the property and any dealings with the property will be subject to the charge of the Union Bank of India for an amount Rs. 13,41,790.55 (Rupees Thirteen Lakhs Forty One Thousand Seven Hundred Ninety and Fifty Five Paisa only and interest thereon.

The borrower's attention is invited to provisions of sub-section (8) of section 13or the Act, in respect of time available to the borrower to redeem the secured assets.

That the property Open Land Adm. Sq. Mt. 207.56 of Plot No. 6, Bearing Revenue Survey No. 1346/P1/P2/P3 with in Limit of Veraval Patan Joint Municipality. Known as Shri Ganesh Park, City: Veraval, Taluka: Veraval, Dist.: GirSomnath, Gujarat Owned by Javeshbhai Babubhai Khapandi.

East: Adj. Existing Gada Marg North: Adj. Plot No.5 West: Adj. 7.50 Mtr. Road South: Public Way

Date : 10.02.2022 Place : Veraval

Authorised Officer Union Bank Of India

HEAD OFFICE: #40-1-144, Corporate Centre, M.G.Road, Vijayawada 520 010. Email ID of the Bank: auctions@ikffinapp.com, Phone No.: 0866-2474644. SALE NOTICE FOR SALE OF IMMOVABLE PROPERTY

APPENDIX-IV-A [See provision to rule 8(6)] E-Auction Sale Notice for Sale of Immovable Assets under the Securitization and Reconstruction of Financial Assets an Enforcement of Security Interest Act, 2002 read with provision to Rule 8 (6) of the Security Interest (Enforcement) Rules, 2002.

Notice is hereby given to the public in general and in particular to the Borrower/s and Guarantor/s that the below described immovab properties mortgaged/ charged to The IKF Finance Ltd, The Physical possession of which have been taken by the Authorized Officer o IKF Finance Ltd, will be sold on "As is where is", "As is what is" and "Whatever there is" basis in e-auction for recovery of the balance due to **The IKF Finance Ltd** from the Borrowers and Guarantors, as mentioned in the table. Details of Borrowers and Guarantors, amount due, Short Description of the immovable property and encumbrances known thereon, possession type, reserve rice and earnest money deposit, Date and Time of Auction are also given as:

Name of Borrowers/Co-Borrowers/Guarantors/Mortgagers: 1) Mrs. Falguni Rajeshbhai Rathod, W/o. Rajeshbhai Babubha Rathod, R/o. 502, Raj Residency, Aashanagar, Navsari, Gujarat-396445, **2) Rajeshbhai Babubhai Rathod, S/o. Babubhai Rathod** R/o. 502, Raj Residency, Aashanagar, Navsari, Gujarath - 396445.

Date & Amount of 13(2) Demand Notice: To pay Rs. 2,44,51,189/- (Rupees Two Crores Forty Four Lakhs Fifty One Thousand One Hundred and Eighty Nine Only) (in respect of Loan Account No.LN-141389 as on 12-09-2019 with further interest at the contractual rate, within 60 days from the date of receipt of the said notice. Demand Notice Dated: 16-09-2019

DESCRIPTION OF PROPERTY

All that property consisting of all the piece and parcel the immovable property I.e., Plot No.97 (City Survey Nondh No.3098 admeasuring 446.00 Sq.Mtrs) of Tika No.60 (Municipal Tenement No.9/1-2146, 9/1-2147) admeasuring area 446.00 Sq.meters along with construction made thereon of "Ashanagar" of the land bearing Block No.28, Revenue Survey No.266/1 paiki of Moje; Navsari, Taluka: Navsari, District Navsari being bounded by: **East**: Road and Khangi Plot No.23, **South**: Adjacent City Survey No.3097, **West**: Road, **North:** Road.

Reserve Price: Rs. 2,50,00,000/-; Earnest Money Deposit: Rs. 25,00,000/-; BID Increment: Rs.20,000/- and in such multiple.

Date & Time of Auction: 18th March' 2022 & Time 10.30 a.m. to 1.00 p.m.

Last Date for Submission of EMD: 10th March' 2022 by 5.00 p.m

Encumbrances Known: Not Known

Earnest Money Deposit Details (EMD) Details: EMD amount to be deposited by way of RTGS/ NEFT to the account details mentioned erein below: A/c No.: 11520200015059, IFSC: FDRL0001152, Bank Name: The Federal Bank Limited, Branch: Governorpe Vijayawada - 520 002, No LIEN A/C (Office Account)

Contact Person & Inspection date: Sri Hardik Harish Joshi, Mob: 989837806.

for detailed terms and conditions of the sale, please refer to the link **http://auctions@ikffinapp.com** and **www.bankeauctions.com** Date: 16.02.2022, Place: Ahmedabad Sd/- Authorised Officer, IKF Finance Limited

UNITED POLYFAB GUJARAT LIMITED CIN: L18109GJ2010PLC062928

Regd Office: Survey No. 238, 239, Shahwadi, Opp. New aarvee Denim, Narol-Sarkhej Highway, Ahmedabad-382 405 Gujarat, India • Tel No: -+91-079-25731155 • Website:www.upgl.in • Email-info@unitedpolyfab.com

(Rs. in Lakhs Except EPS)									
Particulars	Quarter ended on 31/12/2021	Quarter ended on 30/09/2021	Quarter ended on 31/12/2020	Nine Month ended on 31/12/2021	Nine Month ended on 31/12/2020	Year ended on 31/03/2021			
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited			
Total Income From Operations	18718.51	18052.04	7773.65	49517.97	13694.19	21053.08			
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	156.90	591.37	454.66	889.89	(71.10)	214.28			
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	156.90	591.37	454.66	889.89	(71.10)	214.28			
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	110.90	488.69	279.83	750.53	(103.37)	44.51			
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	109.90	487.69	278.83	747.53	(106.37)	40.52			
Equity Share Capital	2095.16	2095.16	2095.16	2095.16	2095.16	2095.16			
Earnings Per Share (of Rs 10/- each) (for continuing and discontinued operations)-									
Basic : (not annualzed for the quarter ended) Diluted:(not annualzed for the quarter ended)	0.53	2.33	4.01	3.58	(1.48)	0.48			
Diluteu.(Hot alliluaizeu for the quarter effueu)	0.53	2.33	4.01	3.58	(1.48)	0.48			

The above financial is an extract of the detailed format of quarterly Financial Results filed with the National Stock Exchange (NSE Ltd.) under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The full format of the quarterly Financial Results are available on the National Stock Exchange Website at www.nseindia.com and Company's website at www.upgl.in. For, United Polyfab Gujarat Limited

GAGAN NIRMALKUMAR MITTAL

Place: Ahmedabad Date: February 15, 2022 CHAIRMAN & MANAGING DIRECTOR DIN: 00593377

यूनियन बैंक (N Union Bank

Veraval Branch: Bhidiya Near Rameshwar Petrol Pump Somnath Road, Veraval - 362265

[Rule 8(1)] **POSSESSION NOTICE** (For immovable property)

Whereas, The undersigned being the authorised officer of Union Bank of India, Bhidiya, Near Rameshwar Petrol Pump, Somnath Road, Veraval 362265 (address of the branch) under the Securitisation and Reconstruction of Financial Assets and Enforcement Security Interest Act, 2002 (Act No. 54 of 2002) and in exercise of powers conferred under Section 13(12) read with rule 3 of the Security Interest (Enforcement) Rules, 2002 issued a demand notice dated 23.11.2021 calling upon the borrower M/s Yagna Sea Food, Prop. Babubhai Lakhambhai Fofandi, Guarantors - Shri Lakhambhai Ramiibhai Fofandi, Smt. Neetaben Kaniibhai Suvani, Mrs. Kanchanben Vithalbhai Jungi, Ms Punamben Vithalbhai Jungi, Mr. Hiren Vithalbhai Jungi, Mr. Akshay Vithalbhai Jungi, Ms Nirupaben Vithalbhai Jungi Legal Heirs of deceased Mr. Vithalbhai V Jungi (Guarantor), Smt. Hiruben Lakhamnbhai Fofandi & M/s Khaiya Export to repay the amount mentioned in the notice being Rs. 5,21,40,088/- (Rupees Five Crore Twenty One Lakhs Forty Thousand Eighty Eight only) within 60 days from the date of receipt of the said notice.

The borrower having failed to repay the amount, notice is hereby given to the borrower and the public in general that the undersigned has taken possession of the property described herein below in exercise of powers conferred on him/her under Section 13(4) of the said Act read with rule 8 of the said rules on this 10th Day of February 2022.

The borrower in particular and the public in general is hereby cautioned not to deal with the property and any dealings with the property will be subject to the charge of the Union Bank of India (name of the Institution) for an amount Rs 5,21,40,088/- (Rupees Five Crore Twenty One Lakhs Forty Thousand Eighty Eight only) and interest thereon

The borrower's attention is invited to provisions of sub-section (8) of section 13of the Act, in respect of time available to the borrower to redeem the secured

Description of Immovable Property

1. The Property Flat No. 404, Sq. Mtr. 40.00 on 4th Floor, Neeldeep Apartmen constructed on land of City Sur. Block No. B, Sur. No. 123/A, Residential purpose and located in the area Krishna Nagar, near Anand Pushpa Bhandar, Khadkhad, City rayal, Gir-Somnath, Owned by **Babulal Lakhambhai Fofandi** Boundary North: Road and Balcony

East: Flat No. 401 and Duck West: Duck and others property South: Staircase and Common Passage 2. The Residential Land Sq. Mtr. 478-00 of Plot No. 9 to 12 bearing R. S. No. 18/2 of Village: Bhalpara, Tal.: Veraval, Dist.: Gir-Somnath, Owned by **Babulal Lakhambha**

Fofandi. Boundary [Joint boundary of Plot No. 9 to 12]: North: Adj. S. No. 18/1 East: Road South: 6-10 Mtr. Road West: Adj. Plot No. 13 3. The Residential House known as "Shiy Krupa" constructed on Land Sq. Mtr. 111-48

of Plot No. 48 and construction there on bearing R. S. No. 366, located at Kamnatl Society, Behind Bhalka Temple, Village: Bhalpara, Tal.: Veraval, Gir-Somnath, Owned by Babulal Lakhambhai Fofandi. Boundary:

North: Road East: Plot No. 49 West: Plot No. 47 South: Plot No. 51

4. The Property – Land and constructed Residential House constructed on Plot No 3 paiki Northen Sided Land Sq. Mtr. 166-54, known as "Krishiv" for Residentia purpose, located at Vivekananda Society, 60 Ft. Road, City Veraval, Tal.: Veraval, Dist Rev. Sur. Gir Somnath Junagadh, under the limit of Veraval - Patan Joint Municipality included in T. P. Scheme No. 1 and given Final Plot No. 156 to the said land bearing Revenue Survey No. 66, and Residential House constructed on the said Plot, Owner by Babulal Lakhambhai Fofandi. Boundary:

North: Plot No. 2 East: 25 Ft. Wide Road West: N. A. land of S. No. 67 South: Plot No. 3 Paiki

Boundary: [Joint boundaries of 6 Shops]

5. That the property - Commercial Property (Shop), Shop No. 1 to 6 (Six Shops) Total Area Sq. Mtr. 68-82 situated at Ground Floor OdAxay Complex constructed on Plot No. 6 of R. S. No. 66 paiki included in T. P. Scheme No. 1, F. P. No. 155 with in limi of Verval - Patan Joint Municipality, located at Vivekanand Society, 60 Ft. Road Veraval, Dist.: Gir-Somnath, Owned by Babulal Lakhambhai Fofandi

East: Adjoining Parking space, Wall Common North: Common way for Axay Apartmen West: Road, Shatter of Shops South: Plot No. 7 of the said N. A. Land **6. That the Property is for Residential** purpose and situated at Village : Veraval, Tal. Veraval, City-Survey Block No. 1, Survey No. 358 paiki land, Sq. Mtr. 19-23-10 and Survey No. 359 land, Sq. Mtr. 76-18-07, Total Sq. Mtr. 95-41-17, located in the area Kharvawad, Pili Sheri, Verval and the property is known as "MotiBhuvan" owned by

Shri Lakhambhai Ramjibhai Fofandi. Boundary: North: Property of Adj. S. No. 286 and S. No. 290 East: Government land

West: Property of Adj. S. No. 288 South: Road 7. The Property is Residential Flat No. 20, Sq. Mtr. 39-00, situated at 4th Floor, Star-A building, constructed on Land of City Survey Block "B", Sur. No. 204/B, paiki of Veraval within limit of verval - Patan Joint Municipality, City, Veraval, Tal. : Veraval, Dist. GirSomnath. owned by Smt. Neetaben Kanjibhai Suyani. Boundary :

East: Flat No. 21 North: Others Property West: Flat No. 19 South: Common Passage and main entrance of Flat on this

side and separate wall of flat on this Side 8. The Property - Land Sq. Mtr. 178-95 of Plot No. 29, Land Sq. Mtr. 189-94 of Plot No. 30, Land Sq. Mtr. 133-28 of Plot No. 31, Land Sq. Mtr. 126-56 of Plot No. 32, and Sq. Mtr. 172-15 of Plot No. 33, Total Sq. Mtr. 800-88 is for the purpose of Resident converted in to Non Agri Land bearing Revenue Survey No. 38/p1 and S. No. 39 of Village: Dabhor, Tal.: Veraval, Dist.: Gir - Somnath, Shri Vithalbhai Veljibhai Jungi

Boundary (Plot No. 29): East: 7-50 Mtr. widen road

North: Adj. Land bearing S. No. 33 West: Adi. Plot No. 22 South: Adi. Plot No. 28 Boundary (Plot No. 30 to 33) :

East: Adj. land of 8 No. 44 North: Adj. Land bearing S. No. 33 West: 7-50 Mtr. Widen Road South: 9-00 Mtr. widen Road 9. The Property is House building constructed on land Sq. Mtr. 96-12-14 of City Survey Block "I", S. No. 346, within limit of Veraval-Patan Joint Municipality, City

Fofandi. Boundary: North: House of Kesharben Ganesh East: Road West: House of Amad Abdul etc. South: House of Pathanchand Punja 10. Hypothecation over the Book Debts and all other Current Assets of the firm

Veraval, Ta.: Veraval, District: Gir-Somnath, owned by Smt. Hiruben Lakhamnbha

(present & future) of M/s Khaiya Export Date : 10.02.2022 **Authorised Officer** Union Bank Of India Place : Veraval

MEERA INDUSTRIES LIMITED MEERA CIN: L29298GJ2006PLC048627

Regd. Office: Plot No. 2126, Road No.2, G.I.D.C., Sachin-394 230. Surat, Gujarat, India. Website: www.meeraind.com

Statement of Consolidated unaudited financial results for the Quarter and Nine Months Ended 31st December, 2021

			_		(Allioui	it iii Lakiis)			
	Consolidated								
	Three Months Ended Nine Months Ended								
SI. Particulars	31.12.2021 (Unaudited)	30.09.2021 (Unaudited)	31.12.2020 (Unaudited)	31.12.2021 (Unaudited)	31.12.2020 (Unaudited)	31.03.2021 (Audited)			
Total Income from Operations (net)	865.43	1,250.09	271.61	2,635.79	1,063.81	2,270.44			
2. Net Profit / (Loss) for the period before									
exceptional items and tax	126.91	262.80	(62.26)	375.99	67.70	285.98			
3. Net Profit / (Loss) for the period before tax	107.67	190.22	(60.03)	282.35	36.81	214.66			
4. Net Profit / (Loss) for the period after tax	108.07	190.62	(59.63)	283.54	38.00	216.25			
5. Total Comprehensive Income for the									
period (after tax)	77.07	186.06	(46.54)	266.55	49.18	213.92			
6. Equity Share Capital	1,067.88	1,067.88	1,067.88	1,067.88	1,067.88	1,067.88			
7. Other equity (excluding revaluation reserves)						1,391.79			
8. Earnings Per Share (of Rs. 10/- each) #									
1. Basic	1.01	1.78	(0.56)	2.64	0.34	2.01			
2. Diluted	1.01	1.78	(0.56)	2.64	0.34	2.01			
#NotAnnualised									

Key Numbers of Standalone Financial Results for the quarter and Nine Months ended 31 December 2021.

	(Amount in Lakhs								
		Three	Months E	nded	Nine Mont	Year Ended			
SI. No.	Particulars	31.12.2021 (Unaudited)	30.09.2021 (Unaudited)		31.12.2021 (Unaudited)		31.03.2021 (Audited)		
1	Total Income from Operations (net)	764.71	1,302.38	271.61	2,586.40	1,045.30	2,224.58		
2	Net Profit / (Loss) for the period before tax	95.91	258.24	(49.53)	359.00	82.76	289.35		
3	Net Profit / (Loss) for the period after tax	76.67	185.66	(46.93)	265.36	47.99	212.33		
4	Total Comprehensive Income for the period (after tax)	77.07	186.06	(46.54)	266.55	49.18	213.92		

Notes:

- The Company has adopted Indian Accounting Standards ('Ind AS'), prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, with effect from April 01, 2020 and accordingly these financial results have been prepared in accordance with Ind AS notified under the Companies (Indian Accounting Standards) Rule, 2015 as amended by the Companies (Indian Accounting Standards) (Amendments) Rules 2016. The Financial results, presented in accordance with Ind AS 101 - First - Time adoption of Indian Accounting Standards, have been prepared in accordance with the recognition and measurement principals in Ind AS 34 - Interim Financial Reporting.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 14, 2022. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.

Previous periods figures have been regrouped and rearranged wherever necessary.

The above is an extract of the detailed format of Quarterly/Period Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Period Financial Results are available on the websites of Stock Exchange www.bseindia.com and the Company For MEERA INDUSTRIES LIMITED

Dharmesh Desai Date: February 14, 2022 Managing Director Place: Surat

parmaX PARMAX PHARMA LIMITED

Reg. off: Plot No. 20, Rajkot Gondal National Highway No.27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot (Gujarat) - 360311. INDIA (CIN: L24231GJ1994PLC023504 Web: www.parmaxpharma.com, E-mail - info@parmaxpharma.com)

Extract of Unaudited Financial Results for the Quarter Nine Months ended 31/12/2021

(Rs. In Lakh)

	Sr. No.	Particulars	Quarter Ended 31/12/2021	Quarter Ended (30/09/2021)	Quarter Ended (31/12/2020)	Nine Months Ended (31/12/2021)	Nine Months Ended (31/12/2020)
l	1	Total income from operations (net)	289.14	656.71	1047.41	1120.91	1887.87
	2	Net Profit / (Loss) for the period (before tax, Exceptional and / or Extraordinary items)	-51.81	114.06	153.68	18.75	105.76
	3 Net Profit / (Loss) for the period before tax (After Exceptional and / or Extraordinary items)		-51.81	114.06	153.68	18.75	105.76
	4	Net Profit / (Loss) for the period After tax (After Exceptional and / or Extraordinary items)	-51.81	114.06	153.68	18.75	105.76
	5			114.06	153.68	18.75	105.76
ſ	6	Equity Share Capital	374.13	374.13	374.13	374.13	374.13
	7	Reserves (excluding Revaluation Reserve as shown in the balance Sheet of previous year)	-	-	-	115.47	167.05
	8	Earning Per Share (before extraordinary items) (of Rs.10/- each)					
		Basic and Diluted EPS	-1.38	3.05	4.11	0.50	2.83
Note The description of the detailed on the Court of American State of the Court of							

Note: The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the Stock Exchange websites (www.bseindia.com) & on Company's website (www.parmaxpharma.com)

Place : Hadamtala

Date : 14th February, 2022

For, Parmax Pharma Limited **Umang Alkesh Gosalia** Managing Director Din No.: 05153830

TAMBOLI CAPITAL LIMITED

Regd. Office: Mahavir Palace, 8A, Kalubha Road, Bhavnagar 364002 Telephone: (91) 886 654 1222 / (91) (278) 252 0065, Fax: (91) 278 252 0064 E-mail: direct1@tambolicapital.in Website: www.tambolicapital.in CIN: L65993GJ2008PLC053613

Statement of Un-audited Financial Results for the Quarter (Q3) and nine months ended December 31, 2021

(₹ in Lacs)

Sr. No.				CONSOL	IDATED			STANDALONE					
NO.	Quarter Ended N		Nine Mon	ths Ended	Year Ended	Quarter Ended			Nine Months Ended		Year Ended		
		31.12.2021 Unaudited	30.09.2021 Unaudited	31.12.2020 Unaudited	31.12.2021 Unaudited	31.12.2020 Unaudited	31.03.2021 Audited	31.12.2021 Unaudited	30.09.2021 Unaudited	31.12.2020 Unaudited	31.12.2021 Unaudited	31.12.2020 Unaudited	31.03.2021 Audited
1.	Total income from Operations	2,037.03	2,120.37	2,269.21	5,784.99	4,859.69	6,754.42	19.74	145.84	70.60	203.70	213.62	239.39
2.	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	316.32	537.88	644.49	1,243.62	911.88	1,270.18	8.30	130.77	7.30	150.95	94.23	108.14
3.	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	316.32	537.88	644.49	1,243.62	911.88	1,270.18	8.30	130.77	7.30	150.95	94.23	108.14
4.	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	217.39	393.39	485.74	897.18	682.38	937.83	6.18	120.66	3.58	135.40	80.94	91.88
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss)	220.42	396.42	483.58	906.27	675.90	949.95	6.18	120.66	3.58	135.40	80.94	91.88
	for the period (after tax) and Other Comprehensive Income (after tax)]												
6.	Equity share capital (Face value Rs. 10 each)	992.00	992.00	992.00	992.00	992.00	992.00	992.00	992.00	992.00	992.00	992.00	992.00
7.	Other Equity (excluding Revaluation Reserves as shown in the balance sheet						7,185.52						593.67
	of previous accounting year ended)												
8.	Earnings Per Share (of Rs. 10/Each (for continuing and discontinued operations)												
	Basic	2.19	3.97	4.90	9.04	6.88	9.45	0.06	1.22	0.04	1.36	0.82	0.93
	Diluted	2.19	3.97	4.90	9.04	6.88	9.45	0.06	1.22	0.04	1.36	0.82	0.93

- 1. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's website www.tambolicapital.in and on the website of Bombay Stock exchange www.bseindia.com under scrip code number 533170.
- 2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

Place: Bhavnagar Date: 14.02.2022

Vaibhav B. Tamboli, Chairman and CEO

ON BEHALF OF THE BOARD OF DIRECTORS

Ahmedabad

Parmax Pharma Limited

Reg. off: Plot No. 20, Rajkot Gondal National Highway No.27 Hadamtala, Tal. Kotda Sangani, Dist. Rajkot (Gujarat) - 360311. INDIA (CIN: L24231GJ1994PLC023504 Web: www.parmaxpharma.com, E-mail-info@parmaxpharma.com)

Extract of Unaudited Financial Results for the Quarter Nine Months ended 31/12/2021

(Rs. In Lai								
Sr. No.	Particulars	Quarter Ended 31/12/2021	Quarter Ended (30/09/2021)	Quarter Ended (31/12/2020)	Nine Months Ended (31/12/2021)	Nine Months Ended (31/12/2020)		
1	Total income from operations (net)	289.14	656.71	1047.41	1120.91	1887.87		
2	Net Profit / (Loss) for the period (before tax, Exceptional and / or Extraordinary items)	-51.81	114.06	153.68	18.75	105.76		
3	Net Profit / (Loss) for the period before tax (After Exceptional and / or Extraordinary items)	-51.81	114.06	153.68	18.75	105.76		
4	Net Profit / (Loss) for the period After tax (After Exceptional and / or Extraordinary items)	-51.81	114.06	153.68	18.75	105.76		
5	Total Comprehensive Income for the period	-51.81	114.06	153.68	18.75	105.76		
6	Equity Share Capital	374.13	374.13	374.13	374.13	374.13		
7	Reserves (excluding Revaluation Reserve as shown in the balance Sheet of previous year)			-	115.47	167.05		
8	Earning Per Share (before extraordinary items) (of Rs.10/- each)							
	Basic and Diluted EPS	-1.38	3.05	4.11	0.50	2.83		
NI-4	- The above to an extra define details	16		I Einen ein I Die				

Note: The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the Stock Exchange websites (www.bseindia.com) & on Company's website (www.parmaxpharma.com)

Place : Hadamtala

Date: 14th February, 2022

For, Parmax Pharma Limited sd/-

Umang Alkesh Gosalia Managing Director Din No. : 05153830

SURYAKRUPA FINANCE LIMITED

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED ON 31st December, 2021

CIN: L60200GJ1986PLC083845

Regd. Office: Plot No. 267, Ward 12/B, Gandhidham, Gujarat-370201 Email: investorsuryakrupa@gmail.com Website: www.suryakrupafinance.in Contact: 9979898027

			Rs. In Lakhs
Particulars	Quarter ended 31.12.2021	Nine Months ended 31.12.2021	Quarter ended 31.12.2020
	(Unaudited)	(Unaudited)	(Unaudited
Total Income from Operations (net)	464.53	464.53	0.00
Net profit for the period (before Tax, Exceptional and Extraordinary items)	20.81	17.06	(0.91)
Net Profit for the period after tax (after Exceptional and Extraordinary Items)	20.81	17.06	(0.91)
Equity Share Capital (Face Value of Rs.10/- each)	100	100	100
Earnings Per Share Basic/ Diluted	2.08	1.71	(0.09)
	D C 1 1		

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the quarterly unaudited financial results are available on the Stock Exchange website: www.bseindia.com and also on Company's website at www.suryakrupafinance.in For, Suryakrupa Finance Ltd.

Place: Gandhidham Date: 15/02/2022

Akansha pithaliya (Compliance Officer)



in Office: No. 196, TTK Road, Alwarpet, Chennai 600 018

SASF

STRESSED ASSETS STABILISATION FUND (SASF) Principal office- IDBI Tower, 3rd Floor, WTC Complex, Cuffe Parade, Mumbai- 400005

SALE OF FINANCIAL ASSET Stressed Assets Stabilisation Fund (SASF), a Government of India Trust,

notified as a Financial Institution by Central Government through its notification dated September 29, 2004 under Section 2(h) (ii) of the Recovery of Debts due to Banks and Financial Institutions Act, 1993, invites bids for sale of one of its financial assets viz. M/s Asian Alloys Limited to the eligible ARCs/Banks NBFCs/FIs on "As is where is and As is what is and without recourse" basis. Brief details of financial asset showcased:-

Name of the Company (Amt. in crore) All Cash 1 M/s Asian Alloys Limited 32.50 For details please visit website www.sasftrust.com and www.idbibank.in. For

further details, you may contact at email- sv.shinde@idbi.co.in and shubhranshu.sahoo@idbi.co.in.SASF reserves the right to accept or reject any bids. n case of any further clarification, the following officers may be contacted:

Shri Santosh V Shinde -Deputy General Manager(SASF) -022-66552048 (M) 8240010549/9969024683. Shri Shubhranshu Sekhar Sahoo -Assistant General Manager (SASF)

022-66552369. (M) 9560523180 Deputy General Manager Stressed Assets Stablisation Fund Date : 16.02.2022



PUBLIC NOTICE

NOTICE IS HEREBY GIVEN THAT (1) FOLIO NO. 1026922 SHARE CERTIFICATE NO. 23872 FOR 205 SHARES OF RS. 2/- (RUPEES 2/- PAIDUP) EACH BEARING DISTINCTIVE NO. 11150586 TO 11150790 AND (2) FOLIO NO. 1026922 SHARES CERTIFICATE NO. 919559 FOR 20 SHARES OF RS. 2/- (RUPEES 2/-PAIDUP) EACH BEARING DISTINCTIVE NO. OF 5830797077 TO 5830797096 TOTAL 225 SHARES (TWO HUNDRED TWENTY FIVE SHARES) OF ICICI BANK LTD. WHICH CIN NO. L65190GJ1994PLC021012, HEAVING ITS REGISTERED OFFICE AT ICICI BANK TOWER NEAR CHAKLI CIRCLE, OLD PADRA ROAD, VADODARA-390007 REGISTERED IN THE NAME OF KAMLESH A SHAH HAVE BEEN LOST. KAMLESH A SHAH HAS APPLIED TO THE COMPANY FOR ISSUE OF DUPLICATE CERTIFICATE. ANY PERSON WHO HAS CLAIM IN RESPECT OF THE SAID SHARE CERTIFICATE SHOULD LODGE SUCH CLAIM WITH THE COMPANY WITH IN 15 DAYS OF THE PUBLICATION OF THIS NOTICE . DATE: 16/FEB./2022



એલેમ્બિક ફાર્માસ્યુટિકલ્સ લિમિટેડ

CIN: L24230GJ2010PLC061123 **૨૭૦૨૮ર્ડ ઓફિસ :** એલેમ્બિક રોડ, વડોદરા - ૩૯૦ ૦૦૩ डोन: +८१ २९५ २२८०५५० ઈ-મેલ: apl.investors@alembic.co.in ใหม่เยือ: www.alembicpharmaceuticals.com

સભ્યોને પોસ્ટલ બેલેટ અને ઈ-વોટિંગ સુવિધા આપવા બાબતની નોટિસ

સભ્યોને આથી જાણ કરવામાં આવે છે કે કંપની અધિનિયમ, ૨૦૧૩ ની કલમ ૧૧૦ ની સાથે વંચાતા કંપનીઝ (મેનેજમેન્ટ એન્ડ એડમિનિસ્ટ્રેશન) નિયમો, ૨૦૧૪, ના નિયમ ૨૦ અને ૨૨ ની જોગવાઈઓ અન્વયે, કોર્પોરેટ મંત્રાલય દ્વારા જારી કરવામાં આવેલ તારીખ ૮મી એપ્રિલ, ૨૦૨૦ ના સામાન્ય પરિપત્ર નંબર ૧૪/૨૦૨૦, તારીખ ૧૩મી એપ્રિલ. ૨૦૨૦ ના સામાન્ય પરિપત્ર નંબર ૧૭/૨૦૨૦, તારીખ ૧૫મી જૂન, ૨૦૨૦ ના સામાન્ય પરિપત્ર નંબર ૨૨/૨૦૨૦, તારીખ ૨૮મી સપ્ટેમ્બર, ૨૦૨૦ ના सामान्य परिपत्र नंजर 33/२०२०, तारीज 39मी डिसेम्जर, २०२० ना सामान्य પરિપત્ર નંબર ૩૯/૨૦૨૦, તારીખ, ૨૩મી જૂન, ૨૦૨૧ ના સામાન્ય પરિપત્ર નંબર ૧૦/૨૦૨૧, અને ૮મી ડિસેમ્બર, ૨૦૨૧ ના સામાન્ય પરિપત્ર નંબર ૨૦/૨૦૨૧ ("એમસીએ પરિપત્રો"), સિક્ચોરિટીઝ એન્ડ એક્સચેન્જ બોર્ડ ઓફ ઈન્ડિયા (લિસ્ટિંગ ઓબ્લિગેશન્સ અને ડિસ્કલોઝર રીક્વાયરમેન્ટસ) રેગ્યુલેશન્સ, ૨૦૧૫ ("સેબી લિસ્ટિંગ રેગ્યુલેશન્સ, ૨૦૧૫") ના નિયમન ૪૪, જનરલ મીટિંગ્સ પર સેક્રેટરીયલ સ્ટાન્ડર્ડ ("SS-2") અને અન્ય લાગુ કાયદા, નિયમો અને વિનિયમો (કોઈપણ વૈદ્યાનિક ફેરફાર અથવા તેના પૂનઃઅધિનિયમ સહિત), કંપનીએ નેશનલ સિક્યોરિટીઝ ડિપોઝિટરી લિમિટેડ ("NSDL") મારફતે તારીખ ૧૦મી ફેબ્રુઆરી, ૨૦૨૨ની પોસ્ટલ બેલેટ નોટિસ ("પોસ્ટલ બેલેટ નોટિસ") ઈ-મેલ દ્વારા મંગળવાર, ૧૫મી ફેબ્રુઆરી, ૨૦૨૨ના રોજ સભ્યોને, ઉપરોક્ત નોટિસમાં ઉલ્લેખિત વિશેષ ઠરાવના સંદર્ભમાં તેમની મંજૂરી માટે મોકલેલ છે.

એમસીએ પરિપત્રોનું પાલન કરતાં, આ પોસ્ટલ બેલેટ નોટિસ ફક્ત ઇલેક્ટ્રોનિક માધ્યમ દ્વારા તે સભ્યોને મોકલવામાં આવેલ છે, જેમના નામ ડિપોઝિટરીઝમાંથી મેળવેલ રજીસ્ટર ઓફ મેમ્બર્સ / લાભાર્થી માલિકોની સૂચિ પર શુક્રવાર, ૧૧મી ફેબ્રુઆરી, ૨૦૨૨ ("કટ-ઓફ તારીખ") ના રોજ દર્શાવેલ છે, અને જેમના ઈ-મેલ એડ્રેસ કંપની / ડિપોઝિટરીઝમાં નોંધાચેલા છે. કટ-ઓફ તારીખ પછી સભ્ય બનેલ વ્યક્તિ માટે પોસ્ટલ બેલેટ નોટિસ ફક્ત માહિતી માટે છે.

વધુમાં, એમસીએ પરિપત્રોનું પાલન કરતાં, કંપનીએ સભ્યો માટે તેમના ઈ-મેલ એડ્રેંસની નોંધણી કરાવવા માટે જરૂરી વ્યવસ્થા કરી છે. જે સભ્યોએ તેમના ઈ-મેલ એડ્રેસ રજસ્ટર કર્યા નથી તેઓને વિનંતી કરવામાં આવે છે કે તેઓ (i) જો શેર ડીમેટ મોડમાં ધરાવતા **હોય, તો ડિપોઝિટરી પાર્ટિસિપન્ટ્સ (**"DP") સાથે નોંધણી કરાવે, જ્યાં તેમના ડીમેટ એકાઉન્ટ્સ છે. અને (ii) જો શેર ફીઝીકલ મોડમાં ધરાવતાં દોય, તો https://linkintime.co.in/EmailReg/Email Register.html ઉપર ક્લિક કरीने नोंधणी કरावे.पोस्टल जेलेट नोटीस इंपनीनी वेजसाઇट www.alembicpharmaceuticals.com ઉપર, સ્ટોક એક્સચેન્જની વેબસાઇટ, બીએસઇ લિમિટેડ www.bseindia.com ઉપર અને નેશનલ સ્ટોક એક્સચેન્જ ઑફ ઇન્ડિયા લિમિટેડ www.nseindia.com ઉપર અને NSDLની વેબસાઇટ www.evoting.nsdl.com ઉપર પણ ઉપલબ્ધ છે.

સભ્યોને વિનંતી કરવામાં આવે છે કે તેઓ તેમની સંમતિ અથવા અસંમતિ માત્ર ઈ-વોટિંગ દ્વારા આપે. ઈ-વોટિંગની સુવિધા NSDL દ્વારા પૂરી પાડવામાં આવે છે. ઈ-વોટિંગ સંબંધિત મહત્વની વિગતો અહીં નીચે આપવામાં આવી છે:

ઇ-વોટિંગનો સમયગાળો શરૂ થશે	બુધવાર, ૧૬મી ફેબ્રુઆરી, ૨૦૨૨ના રોજ સવારે૯:૦૦ કલાકે IST.
ઇ-વોટિંગનો સમયગાળો સમાપ્ત થશે	ગુરુવાર, ૧૭મી માર્ચ, ૨૦૨૨ના રોજ સાંજે ૫:૦૦ કલાકે IST. ત્યારબાદ NSDL દ્વારા ઈ-વોટિંગ મોડચુલને બંધ કરવામાં આવશે.

ઈ-વોટિંગ માટેની સૂચનાઓ પોસ્ટલ બેલેટ નોટિસમાં આપવામાં આવી છે. ઉપરોક્ત નોટિસમાં એવા સભ્યો માટે લોગિન ક્રેડેન્શિયલ સંબંધિત સૂચનાઓ પણ શામેલ છે, જે ફીઝીકલ મોડમાં અથવા ડીમેટ મોડમાં શેર ધરાવે છે અને જેમણે કંપની અથવા તેમના DP સાથે તેમના ઈ-મેલ એડ્રેસની નોંધણી કરાવી નથી.

ઈ-વોટિંગ સાથે સંકળાચેલ કોઈપણ પ્રશ્નો/ફરિચાદો હોય; તો તમે શેરધારકો માટે વારવાર પૂછાતા પ્રશ્નો (FAQs), અને શેરધારકો માટે ઈ-વોટિંગ યુઝર મેન્યુઅલ NSDLની વેબસાઇટ www.evoting.nsdl.com ના ડાઉનલોડ વિભાગમાં ઉપલબ્ધ છે તેનો સંદર્ભ લઈ શકો છો અથવા ટોલ ફ્રી નંબરઃ ૧૮૦૦-૧૦૨૦-૯૯૦ અને ૧૮૦૦-૨૨૪-૪૩૦ ઉપર કૉલ કરી શકો છો અથવા કુમારી સોની સિંઘ ને evoting@nsdl.co.in ઉપર વિનંતી મોકલી શકો છો .

એલેમ્બિક ફાર્માસ્થુટિકલ્સ લિમિટેડ વતી,

સ્થળઃ વડોદરા ચરનદીપ સિંઘ સલુજા **તારીખ :** ૧૫મી ફેબ્રુઆરી, ૨૦૨૨ કંપની સેકેટરી

આ નોટીસ કંપનીની વેબસાઇટ www.alembicpharmaceuticals.com ઉપર ઇન્વેસ્ટર સેકશનમાં અને સ્ટોક એક્સચેન્જની વેબસાઇટ www.bseindia.com અને www.nseindia.com ઉપર કોર્પોરેટ એનાઉન્સમેન્ટ સેકશનમાં પણ ઉપલબ્ધ છે.

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA

PUBLIC ANNOUNCEMENT

MYCLEOD?

MACLEODS PHARMACEUTICALS LIMITED

Our Company was originally incorporated as 'Macleods Pharmaceuticals Private Limited' at Mumbai, Maharashtra as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated June 5, 1989, issued by the Registrar of Companies, Maharashtra, at Mumbai ("Roc"). Thereafter, our Company was converted into a public limited company and consequently the name of our Company was changed to 'Macleods Pharmaceuticals Limited' pursuant to a fresh certificate of incorporation dated January 30, 1997 issued by the Roc. For further details in relation to the changes in the name and registered office of our Company, see "History and Certain Corporate Matters" on page 199 of the Draft Red Herring Prospectus dated February 15, 2022 (**"DRHP"**)

Registered Office: 304, Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai - 400059, Maharashtra, India.

Corporate Office: 501-503, "A" Wing, Everest Grande, Shanti Nagar Mahakali Caves Road, Andheri (East), Mumbai - 400093, Maharashtra, India; Telephone: 022-67695800; Contact Person: Siddhesh Mahadeo Rane, Company Secretary and Compliance Officer, E-mail: investors@macleodspharma.com; Website: www.macleodspharma.com; Corporate Identity Number: U24239MH1989PLC052049 PROMOTERS OF OUR COMPANY: GIRDHARILAL BAWRI, BANWARILAL BAWRI AND DR. RAJENDRA AGARWAL

INITIAL PUBLIC OFFER OF UP TO 60,482,040 EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH ("EQUITY SHARES") OF MACLEODS PHARMACEUTICALS LIMITED ("COMPANY") FOR CASH AT A PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A

PREMIUM OF ₹ [●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION (THE "OFFER") THROUGH AN OFFER FOR SALE OF UP TO 6,370,275 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY GIRDHARILAL

BAWRI, UP TO 8,955,582 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BANWARILAL BAWRI AND UP TO 5,280,514 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY DR. RAJENDRA AGARWAL, (COLLECTIVELY, THE "PROMOTER SELLING SHAREHOLDERS") AND UP TO 7,630,901 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY PRATEEK AGARWAL, UP TO 6,582,955 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY AGARWAL, UP TO 8,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BANWARILAL BAWRI AND UP TO 7,630,901 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BANWARILAL BAWRI AND UP TO 7,630,901 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BANWARILAL BAWRI AND UP TO 5,280,514 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BANWARILAL BAWRI AND UP TO 5,280,514 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BANWARILAL BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BANWARILAL BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BANWARILAL BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BANWARILAL BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BANWARILAL BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BANWARILAL BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BAWRI AND UP TO 5,000,001 EQUITY SHARES AGGREGATING UP TO \$[●] MILLION BY BAW 6,313,461 EQUITY SHARES AGGREGATING UP TO ₹[♠] MILLION BY VIJAY AGARWAL, UP TO 4,933,239 EQUITY SHARES AGGREGATING UP TO ₹[♠] MILLION BY ANJU AGARWAL, UP TO 4,893,242 EQUITY SHARES AGGREGATING UP TO ₹[♠] MILLION BY GAURI AGARWAL, UP TO 4,851,700 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY DR. RUCHI AGARWAL, UP TO 2,678,815 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY DR. RUCHI AGARWAL, UP TO 2,678,815 EQUITY SHARES AGGREGATING UP TO ₹ SHARES AGGREGATING UP TO ₹[●] MILLION BY SHALINI KEDIA, UP TO 694,490 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY ANUSHREE AGARWAL AND UP TO 490,870 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY TARADEVI BAWRI (COLLECTIVELY, THE "PROMOTER GROUP SELLING SHAREHOLDERS" TOGETHER WITH PROMOTER SELLING SHAREHOLDERS" SELLING SHAREHOLDERS") AND SUCH EQUITY SHARES OFFERED BY THE SELLING

THE OFFER INCLUDES A RESERVATION OF UP TO [●]* EQUITY SHARES, AGGREGATING UP TO ₹ [●] MILLION (CONSTITUTING UP TO [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES ("EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS "NET OFFER". THE OFFER AND NET OFFER SHALL CONSTITUTE [●]% AND [●]%, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY, RESPECTIVELY.

THE FACE VALUE OF EQUITY SHARES IS ₹1 EACH. THE PRICE BAND, THE RUPEE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY AND THE PROMOTER SELLING SHAREHOLDERS, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS AND WILL BE ADVERTISED IN ALL EDITIONS OF ENGLISH NATIONAL DAILY NEWSPAPER, [•], ALL EDITIONS OF HINDI NATIONAL DAILY NEWSPAPER, [•], AND [•] EDITIONS OF THE MARATHI DAILY NEWSPAPER, [•], (MARATHI BEING THE REGIONAL LANGUAGE OF MAHARASHTRA, WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE", AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES.

*OUR COMPANY AND THE PROMOTER SELLING SHAREHOLDERS IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, MAY OFFER A DISCOUNT OF UP TO [●]% OF THE OFFER PRICE (EQUIVALENT OF ₹[●] PER EQUITY SHARE) TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION. IN ACCORDANCE WITH THE SEBI ICDR REGULATIONS.

In case of any revision to the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days following such revision of the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company and the Promoter Selling Shareholders, in consultation with the Book Running Lead Managers, may for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of three Working Days, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the Book Running Lead Managers and at the terminals of the Syndicate Members and by intimation to Self-Certified Syndicate Banks ("SCSBs"), other Designated Intermediaries and the Sponsor Bank, as applicable

This Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Reguirements) Regulations 2018, as amended ("SEBI ICDR Regulations"). The Offer is being made in accordance with Regulation 6(1) of the SEBI ICDR Regulations and through the Book Building Process wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs", and such portion, the "QIB Portion"). Our Company and the Promoter Selling Shareholders may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), out of which at least one-third shall be available for allocation to domestic Mutual Funds only, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders other than Anchor Investors, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis or in any other manner as introduced under applicable laws, to Non-Institutional Bidders and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders ("RIBs") in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All Bidders, other than Anchor Investors, are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective bank account (including UPIID in case of RIBs) which will be blocked by the SCSBs or the Sponsor Bank as applicable, to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. For details, see "Offer Procedure" on page 479 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP with the Securities and Exchange Board of India ("SEBI") on February 15, 2022. Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI shall be made public for comments, if any, for a period of at least 21 days from the date of such filing by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at, www.bseindia.com, www.nseindia.com, respectively and the websites of the BRLMs, i.e. Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, Edelweiss Financial Services Limited, ICICI Securities Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.investmentbank.kotak.com, www.online.citibank.co.in, www.edelweissfin.com, www.icicisecurities.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI, with respect to disclosures made in the DRHP. The members of the public are requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5.00 p.m. on the 21st day from the aforesaid date of filing of the DRHP with SEBI.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision. Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by the SEBL nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" on page 36 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the DRHP. The Equity Shares, when offered through the Red Herring Prospectus, are proposed to be listed on BSE and NSE For details of the share capital and capital structure and the names of the signatories to the memorandum and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 87 of the DRHP. The liability of

the members of our Company is limited. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 199 of the DRHP.								
	REGISTRAR TO THE OFFER							
Exercise kotak * Investment Banking	cîti	* Edelweiss Ideas create, values protect	Ficici Securities	NOMURA	▲ KFINTECH			
Kotak Mahindra Capital Company Limited 1st Floor, 27 BKC, Plot No. 27, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India Tel: +91 22 4336 0000 E-mail: macleods.ipo@kotak.com Website: www.investmentbank.kotak.com Investor Grievance ID: kmccredressal@kotak.com Contact Person: Ganesh Rane SEBI Registration No.: INM000008704	Citigroup Global Markets India Private Limited 1202, First International Financial Center Bandra Kurla Complex, Bandra (East), Mumbai - 400 098, Maharashtra, India Tel: +91 22 6175 9999 E-mail: macleodspharma.ipo@citi.com Website: www.online.citibank.co.in Investor Grievance ID: investors.cgmib@citi.com Contact Person: Keshav Tawari SEBI Registration No: INM000010718	Edelweiss Financial Services Limited 6" Floor, Edelweiss House, Off C.S.T. Road, Kalina Mumbai - 400 098, Maharashtra, India Tel: +91 22 4009 4400 E-mail: macleods.ipo@edelweissfin.com Investor Grievance E-mail: customerservice.mb@edelweissfin.com Website: www.edelweissfin.com Contact Person: Lokesh Shah SEBI Registration No.: IINM0000010650	ICICI Securities Limited ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, Maharashtra, India Tel: +91 22 6807 7100 E-mail: macleods.ipo@icicisecurities.com Website: www.icicisecurities.com Investor Grievance ID: customercare@icicisecurities.com Contact Person: Sameer Purohit/ Gaurav Mittal SEBI Registration Number: INM000011179	Nomura Financial Advisory and Securities (India) Private Limited Ceejay House, Level 11 Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai – 400 018, Maharashtra, India Tel: +91 22 4037 4037 E-mail: macleodspharmaipo@nomura.com Investor Grievance E-mail: investorgrievances-in@nomura.com Website: www.nomuraholdings.com/company/group/asia/india/index.html Contact Person: Vishal Kanjani/ Chirag Shah SEBI Registration No.: INM000011419	Kfin Technologies Private Limited (formerly known as Karvy Fintech Private Limited) Selenium, Tower B, Plot No 31 and 32 Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy - 500 032, Telangana, India Tel: +91 40 6716 2222 E-mail: mpl.ipo@kfintech.com Website: www.kfintech.com Investor Grievance ID: einward.ris@kfintech.com Contact Person: M Murali Krishna SEBI Registration Number: INR000000221			

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

Place: Mumba

Date: February 15, 2022

For MACLEODS PHARMACEUTICALS LIMITED On behalf of the Board of Directors

Company Secretary and Compliance Officer

MACLEODS PHARMACEUTICALS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI on February 15, 2022. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs, i.e. Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, Edelweiss Financial Services Limited, ICICI Securities Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.investmentbank.kotak.com, www.online.citibank.co.in, www.edelweissfin.com, www.icicisecurities.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section entitled "Risk Factors" on page 36 of the DRHP. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States

only to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act and referred to in the Draft Red Herring Prospectus as "U.S. QIBs") in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions" as defined in, and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. For the avoidance of doubt, the term "U.S. QIBs" does not refer to a category of institutional investors defined under applicable Indian regulations and referred to in the Draft Red Herring Prospectus as "QIBs". There will be no public offering of the Equity Shares in the United States